• Publications
  • Influence
A quiet revolution in global public health: The World Health Organization’s Prequalification of Medicines Programme
WHO PQP’s greatest achievement is improved quality of life-saving medicines used today by millions of people in developing countries, which has made it possible to believe that everyone in the world will have access to safe, effective, and affordable medicines. Expand
Innovation and Access to Medicines for Neglected Populations: Could a Treaty Address a Broken Pharmaceutical R&D System?
A global health R&D treaty is argued for to improve innovation in new medicines and strengthening affordability, sustainable financing, efficiency in innovation, and equitable health-centered governance. Expand
The UNITAID Patent Pool Initiative: Bringing Patents Together for the Common Good
The patent pool will be a voluntary mechanism, meaning its success will largely depend on the willingness of pharmaceutical companies to participate and commit their IP to the pool. Expand
Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001–2016
The use of TRIPS flexibilities to access lower-priced generic medicines between 2001 and 2016 was found to be more frequent than is commonly assumed and the practical, legal pathway provided by TRIPSflexibilities for accessing lower-cost generic equivalents is increasingly important. Expand
We urge WHO to act on cytomegalovirus retinitis.
World leadership is needed to provide cytomegalovirus diagnosis and treatment guidelines, support countries’ efforts to scale up diagnosis, and explore the possibility of integration of routine eye screening with indirect ophthalmoscopy into routine care for all patients first. Expand
Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation
EU pharmaceutical legislation should be amended to allow waivers to data and market exclusivity in cases of public health need and when a compulsory or government use license has been issued, modelled after existing waivers in the EU Regulation on compulsory licensing of patents. Expand
Essential medicines for universal health coverage
Author(s): Wirtz, Veronika J; Hogerzeil, Hans V; Gray, Andrew L; Bigdeli, Maryam; de Joncheere, Cornelis P; Ewen, Margaret A; Gyansa-Lutterodt, Martha; Jing, Sun; Luiza, Vera L; Mbindyo, Regina M;Expand
Pathways to ensure universal and affordable access to hepatitis C treatment
Direct-acting antivirals have dramatically changed the landscape of hepatitis C treatment and prevention, but the discrepancy in DAA prices across low-, middle- and high-income countries is considerable, representing a major barrier for the scale-up of treatment and elimination. Expand
Innovative strategies for the elimination of viral hepatitis at a national level: A country case series
Eight case studies from a diverse range of countries that have invested in responses to viral hepatitis and adopted innovative approaches to tackle their respective epidemics provide models for planning, investment and implementation strategies for other countries facing similar challenges and resource constraints. Expand